MARKET

XLRN

XLRN

Acceleron
NASDAQ

Real-time Quotes | Nasdaq Last Sale

159.84
+5.40
+3.50%
After Hours: 159.90 +0.06 +0.04% 16:00 09/23 EDT
OPEN
154.69
PREV CLOSE
154.44
HIGH
161.35
LOW
154.57
VOLUME
767.90K
TURNOVER
--
52 WEEK HIGH
161.35
52 WEEK LOW
99.98
MARKET CAP
9.73B
P/E (TTM)
-43.1568
1D
5D
1M
3M
1Y
5Y
SVP And General Counsel Sec. Of Acceleron Pharma Trades $1.21 Million In Company Stock
Adam M Veness, SVP And General Counsel Sec. at Acceleron Pharma (NASDAQ:XLRN), made a large buy and sell of company shares on September 21, according to a new SEC filing.
Benzinga · 6h ago
Acceleron Pharma Inc (XLRN) EVP, Chief Commercial Officer Sujay Kango Sold $750,150 of Shares
GuruFocus News · 8h ago
Acceleron Pharma Stock Meets 80-Plus Relative Strength Rating Benchmark
Acceleron Pharma shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 64 to 83.
Investor's Business Daily · 1d ago
BARON INVESTMENT FUNDS TRUST (f Buys SoFi Technologies Inc, SoFi Technologies Inc, Endeavor ...
GuruFocus News · 09/13 19:38
Credit Suisse 'Top of the Crop' list jumps to 9 names for September: At the Open
Credit Suisse ramps up the list of best-of-the-best stocks for September and is adding four new Top Outperform ideas. Credit Suisse Product Manager Andrew St. Pierre defines the "Top of
Seekingalpha · 09/10 12:04
Insider Sell: Acceleron Pharma
MT Newswires · 09/09 17:25
These are Credit Suisse’s favorite stock picks heading into September
Here are 10 of Credit Suisse's top outperform stocks for the month of September.
CNBC.com · 09/09 16:19
Investing in Acceleron Pharma (NASDAQ:XLRN) five years ago would have delivered you a 304% gain
For many, the main point of investing in the stock market is to achieve spectacular returns. And highest quality...
Simply Wall St. · 08/23 19:56
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XLRN. Analyze the recent business situations of Acceleron through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XLRN stock price target is 154.50 with a high estimate of 180.00 and a low estimate of 113.00.
EPS
Institutional Holdings
Institutions: 363
Institutional Holdings: 56.76M
% Owned: 93.20%
Shares Outstanding: 60.90M
TypeInstitutionsShares
Increased
89
2.71M
New
44
1.13M
Decreased
82
3.23M
Sold Out
29
499.16K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Non-Executive Chairman/Independent Director
Francois Nader
President/Chief Executive Officer/Director
Habib Dable
Chief Financial Officer/Senior Vice President/Treasurer
Kevin Mclaughlin
Executive Vice President
Jay Backstrom
Executive Vice President
Sujay Kango
Senior Vice President/General Counsel/Secretary
Adam Veness
Independent Director
Laura Hamill
Independent Director
Christopher Hite
Independent Director
Terrence Kearney
Independent Director
Kemal Malik
Independent Director
Thomas McCourt
Independent Director
Karen Smith
Independent Director
Joseph Zakrzewski
No Data
About XLRN
Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Webull offers kinds of Acceleron Pharma Inc stock information, including NASDAQ:XLRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XLRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XLRN stock methods without spending real money on the virtual paper trading platform.